First Patient with Chronic Hepatitis B Dosed with ISA104 in First-in-Human Phase 1 Study

31 Aug 2023

Study by Erasmus MC marks first clinical development milestone for ISA104 immunotherapeutic treatment of chronic hepatitis B infection

Oegstgeest, The Netherlands, 31 August 2023 – ISA is pleased to announce that the first patient has been dosed in the HEB-PEP study. This first-in-human (FIH) phase 1 study investigates the use of ISA104, a novel treatment aimed to establish functional cure in Chronic Hepatitis B patients. Dosing took place at the Liver Unit of the Erasmus Medical Center in Rotterdam, the sponsor of this dose escalation study.

The HEB-PEP study will investigate the safety, tolerability and efficacy of different doses of ISA104 in

Read more »